Jahn, Henriette

[["dc.bibliographiccitation.firstpage","340"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","American Journal of Medical Genetics Part B: Neuropsychiatric Genetics"],["dc.bibliographiccitation.lastpage","345"],["dc.bibliographiccitation.volume","156B"],["dc.contributor.author","Papiol, Sergi"],["dc.contributor.author","Begemann, Martin"],["dc.contributor.author","Rosenberger, Albert"],["dc.contributor.author","Friedrichs, Heidi"],["dc.contributor.author","Ribbe, Katja"],["dc.contributor.author","Grube, Sabrina"],["dc.contributor.author","Schwab, Markus H."],["dc.contributor.author","Jahn, Henriette"],["dc.contributor.author","Gunkel, Stefan"],["dc.contributor.author","Benseler, Fritz"],["dc.contributor.author","Nave, Klaus-Armin"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2017-09-07T11:46:36Z"],["dc.date.available","2017-09-07T11:46:36Z"],["dc.date.issued","2011"],["dc.description.abstract","By pure endpoint diagnosis of the disease, the risk of developing schizophrenia has been repeatedly associated with specific variants of the neuregulin1 (NRG1) gene. However, the role of NRG1 in the etiology of schizophrenia has remained unclear. Since Nrg1 serves vital functions in early brain development of mice, we hypothesized that human NRG1 alleles codetermine developmentally influenced readouts of the disease: age of onset and positive symptom severity. We analyzed 1,071 comprehensively phenotyped schizophrenic/schizoaffective patients, diagnosed according to DSM-IV-TR, from the GRAS (Göttingen Research Association for Schizophrenia) Data Collection for genetic variability in the Icelandic region of risk in the NRG1 gene. For the case-control analysis part of the study, we included 1,056 healthy individuals with comparable ethnicity. The phenotype-based genetic association study (PGAS) was performed on the GRAS sample. Instead of a risk constellation, we detected that several haplotypic variants of NRG1 were, unexpectedly, less frequent in the schizophrenic than in the control sample (mean OR=0.78, range between 0.68 and 0.85). In the PGAS we found that these \"protective\" NRG1 variants are specifically underrepresented in subgroups of schizophrenic subjects with early age of onset and high positive symptom load. The GRAS Data Collection as a prerequisite for PGAS has enabled us to associate protective NRG1 genotypes with later onset and milder course of schizophrenia."],["dc.identifier.doi","10.1002/ajmg.b.31168"],["dc.identifier.gro","3150547"],["dc.identifier.pmid","21234898"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7321"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.title","A phenotype-based genetic association study reveals the contribution of neuregulin1 gene variants to age of onset and positive symptom severity in schizophrenia"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.contributor.author","Ehrenreich, Hannelore"],["dc.contributor.author","Jahn, H."],["dc.contributor.author","Heutelbeck, K."],["dc.contributor.author","Reinhold, Jennifer"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Wagner, Thilo"],["dc.contributor.author","Wolff-Menzler, C."],["dc.contributor.author","Ahrens, T."],["dc.contributor.author","Haase, A."],["dc.contributor.author","Mahlke, Kristin"],["dc.contributor.author","Maul, Oliver"],["dc.contributor.author","Rusteberg, W."],["dc.contributor.author","Krampe, Henning"],["dc.contributor.editor","Mann, Karl"],["dc.date.accessioned","2017-09-07T11:45:48Z"],["dc.date.available","2017-09-07T11:45:48Z"],["dc.date.issued","2002"],["dc.identifier.gro","3150457"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7223"],["dc.language.iso","de"],["dc.notes.status","final"],["dc.notes.submitter","chake"],["dc.publisher","Pabst Science Publishers"],["dc.publisher.place","Lengerich"],["dc.relation.ispartof","Neue Therapieansätze bei Alkoholproblemen"],["dc.title","ALITA - neue Wege in der ambulanten Intensivbehandlung von Alkoholabhängigen"],["dc.type","book_chapter"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","195"],["dc.bibliographiccitation.issue","3-4"],["dc.bibliographiccitation.journal","Metabolic Brain Disease"],["dc.bibliographiccitation.lastpage","206"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.contributor.author","Aust, Carlotta"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Jahn, Henriette"],["dc.contributor.author","Jacob, Sonja"],["dc.contributor.author","Herrmann, Manfred"],["dc.contributor.author","Sirén, Anna-Leena"],["dc.date.accessioned","2017-09-07T11:46:24Z"],["dc.date.available","2017-09-07T11:46:24Z"],["dc.date.issued","2004"],["dc.description.abstract","With the increased life expectancy in western industrialized countries, the incidence and prevalence of brain diseases dramatically increased. Stroke and a wide spectrum of neuropsychiatric illnesses such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic head injury, and schizophrenia all lead to severe disability. However, targeted effective therapies for treatment of these diseases are lacking. Even more frustrating is the fact that we do not yet clearly understand the basic mechanisms underlying the disease processes in these conditions. We propose a hypothesis of loss of neuronal function via a final common deleterious pathway in this clinically very heterogeneous disease group. This review presents a novel neuroprotective concept for treatment of brain disease: Erythropoietin (EPO). EPO is a natural body-own-protein hormone that has been used for treatment of anemia for more than a decade. The neuroprotective approach using EPO in brain disease represents a totally new frontier. The “Göttingen EPO-stroke trial” represents the first effective use in man of a neuroprotective therapy in an acute brain disease while the experimental EPO therapy to combat cognitive decline in patients with schizophrenia will be introduced as an example of a neuroprotective strategy for a chronic brain disease."],["dc.identifier.gro","3150507"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7279"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.issn","0885-7490"],["dc.subject","EPO; stroke; schizophrenia; treatment; regeneration."],["dc.title","Erythropoietin: Novel approaches to neuroprotection in human brain disease"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","619"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Journal of Psychiatric Research"],["dc.bibliographiccitation.lastpage","635"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Wagner, Thilo"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Reinhold, Jennifer"],["dc.contributor.author","Jahn, Henriette"],["dc.contributor.author","Mahlke, Kristin"],["dc.contributor.author","Barth, Ulrike"],["dc.contributor.author","Sieg, Sonja"],["dc.contributor.author","Maul, Oliver"],["dc.contributor.author","Galwas, Claudia"],["dc.contributor.author","Aust, Carlotta"],["dc.contributor.author","Kröner-Herwig, Birgit"],["dc.contributor.author","Brunner, Edgar"],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Henn, Fritz"],["dc.contributor.author","Rüther, Eckart"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2017-09-07T11:46:24Z"],["dc.date.available","2017-09-07T11:46:24Z"],["dc.date.issued","2004"],["dc.description.abstract","It is far from clear how comorbidity changes during alcoholism treatment. This study investigates: (1) the course of comorbid Axis I disorders in chronic alcoholics over 2 years of controlled abstinence in the outpatient long-term intensive therapy for alcoholics (OLITA) and (2) the effect of comorbid Axis I and II disorders in this group of patients on subsequent drinking outcome over a four-year follow-up. This prospective treatment study evaluates psychiatric variables of 89 severely affected chronic alcohol dependent patients on admission (t1), month 6 (t2), 12 (t3) and 24 (t4). Drinking outcomes have been analyzed from 1998 to 2002. On admission, 61.8% of the patients met criteria for a comorbid Axis I disorder, 63.2% for a comorbid personality disorder. Axis I disorders remit from t1 (59.0% ill), t2 (38.5%), t3 (28.2%) to t4 (12.8%) (p<0.0001). Anxiety disorders remit more slowly from t1 (43.6%) to t3 (20.5%, p=0.0086), whereas mood disorders remit early between t1 (23.1%) and t2 (5.1%, p=0.0387) with a slight transient increase at t3 (10.3%). During the four-year follow-up, the cumulative probability of not having relapsed amounts to 0.59. Two predictors have a strong negative impact on abstinence probability: number of inpatient detoxifications (p=0.0013) and personality disorders (p=0.0106). The present study demonstrates a striking remission of comorbid Axis I disorders upon abstinence during comprehensive long-term outpatient alcoholism treatment. The presence of an Axis II rather than an Axis I disorder on admission strongly predicts drinking outcome over a four-year follow-up"],["dc.identifier.doi","10.1016/j.jpsychires.2004.04.007"],["dc.identifier.gro","3150506"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7278"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.issn","0022-3956"],["dc.subject","Outpatient alcoholism treatment; Chronic alcohol dependence; Prognosis; Comorbid personality disorders; Chronicity; Chronic psychiatric illness"],["dc.title","Substantial decrease of psychiatric comorbidity in chronic alcoholics upon integrated outpatient treatment - results of a prospective study"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","135"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Substance Use & Misuse"],["dc.bibliographiccitation.lastpage","178"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Wagner, Thilo"],["dc.contributor.author","Küfner, Heinrich"],["dc.contributor.author","Jahn, Henriette"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Reinhold, Jennifer"],["dc.contributor.author","Timner, Wiebke"],["dc.contributor.author","Kröner-Herwig, Birgit"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2017-09-07T11:46:23Z"],["dc.date.available","2017-09-07T11:46:23Z"],["dc.date.issued","2004"],["dc.description.abstract","For nine years, the so-called \"therapist rotation\" has been a central part of OLITA, the Outpatient Longterm Intensive Therapy for Alcoholics. Thus far, the participation of several equally responsible therapists in the treatment of a patient has rarely been seen as a specific therapeutic approach. The present article analyzes the therapist rotation from a theoretical and clinical perspective. Articles concerned with the therapeutic alliance in the treatment of substance use disorders are reviewed. Furthermore, the literature on multiple psychotherapy, which may be seen as the precedent of the therapist rotation is surveyed. Based on the efficacy of multiple psychotherapy and the importance of the therapeutic alliance in the treatment of substance use disorders, the present work discusses the therapist rotation as an essential factor for the success of OLITA. It considers both potential advantages and disadvantages for patients and therapists and tries to identify conditions under which this approach appears to promote therapeutic interactions. Finally, the implementation of therapist rotation into OLITA is described, including the theoretical background of the program itself and the treatment procedure. New areas of application for the therapist rotation are discussed."],["dc.identifier.doi","10.1081/JA-120027769"],["dc.identifier.gro","3150504"],["dc.identifier.pmid","15002947"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7276"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.issn","1082-6084"],["dc.subject","Alcohol dependence; Multiple psychotherapy; Outpatient treatment; Therapist rotation; Therapeutic alliance; Therapeutic relationship; Common factors; Unique factors"],["dc.title","Therapist rotation - A new element in the outpatient treatment of alcoholism"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","403"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Addiction Biology"],["dc.bibliographiccitation.lastpage","407"],["dc.contributor.author","Haber, H."],["dc.contributor.author","Jahn, H."],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.contributor.author","Melzig, M. F."],["dc.date.accessioned","2017-09-07T11:45:31Z"],["dc.date.available","2017-09-07T11:45:31Z"],["dc.date.issued","2002"],["dc.description.abstract","Endogenous 6,7-dihydroxy-1-methyl-1,2,3,4- tetrahydroisoquinoline (salsolinol) could be a potential marker involved in the aetiology of alcoholism. Whereas the amount of salsolinol in plasma and urine depends on several dietary conditions, the salsolinol from peripheral mononuclear cells should be formed endogenously. Salsolinol was quantified in lymphocytes of 10 controls and 11 alcoholics (after 1 and 13 weeks of abstinence) using solid phase extraction and gas chromatography/mass spectrometry. Alcoholics showed significantly lower salsolinol concentration than the controls. After 13 weeks of abstinence a further significant decrease of SAL levels could be seen in the lymphocytes of alcoholics. The findings of this study support the theory that salsolinol might be a trait marker in alcoholism."],["dc.identifier.gro","3150395"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7155"],["dc.language.iso","en"],["dc.notes.status","zu prüfen"],["dc.relation.issn","1355-6215"],["dc.title","Assay of salsolinol in peripheral blood mononuclear cells of alcoholics and healthy subjects by gas chromatography-mass spectrometry"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","75"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Gesprächspsychotherapie und Personzentrierte Beratung"],["dc.bibliographiccitation.lastpage","84"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Wagner, Thilo"],["dc.contributor.author","Reinhold, Jennifer"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Mahlke, Kristin"],["dc.contributor.author","Galwas, Claudia"],["dc.contributor.author","Barth, U."],["dc.contributor.author","Aust, Carlotta"],["dc.contributor.author","Haase, A."],["dc.contributor.author","Jahn, H."],["dc.contributor.author","Kroner-Herwig, Birgit"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2017-09-07T11:45:47Z"],["dc.date.available","2017-09-07T11:45:47Z"],["dc.date.issued","2003"],["dc.identifier.gro","3150459"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7225"],["dc.language.iso","de"],["dc.notes.status","zu prüfen"],["dc.title","Therapeutenrotation - erfolgreich für Alkoholkranke, erleichternd für Therapeuten : Therapieprozess} bei ALITA (Ambulante Langzeit - Intensivtherapie für Alkoholkranke) : Multiple Beziehungsgestaltung in der integrativen Therapie chronisch psychisch kranker Menschen"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1925"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Alcoholism: Clinical and Experimental Research"],["dc.bibliographiccitation.lastpage","1930"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Jahn, Henriette"],["dc.contributor.author","Döring, Wolf K. H."],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Sieg, Sonja"],["dc.contributor.author","Werner, Carola"],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Brunner, Edgar"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2017-09-07T11:45:44Z"],["dc.date.available","2017-09-07T11:45:44Z"],["dc.date.issued","2004"],["dc.description.abstract","Background: Basal arginine vasopressin (AVP) plasma levels in alcoholic patients are persistently decreased over months of controlled alcohol abstinence. As a potential explanation of this phenomenon, a reduction of AVP immunoreactive neurons was described in the hypothalamus of alcohol-dependent humans and rodents. This study was therefore designed to examine whether long-term abstinent alcoholics have a compromised response of AVP to osmostimulation.Methods: Fifteen male alcoholics, aged 42 ± 2 years, were examined (1) over 12 months of strictly controlled abstinence (longitudinal study) and (2) during an osmostimulation test (5% NaCl infusion at 0.06 ml/kg/min over 2 hr) and were compared with 15 healthy male subjects, aged 41 ± 2 years. AVP and routine laboratory parameters, including electrolytes and osmolality, were measured.Results: Starting from lower basal concentrations, alcoholics showed increases similar to those of controls in AVP and plasma osmolality after osmostimulation. The first sensation of thirst was announced significantly later by alcoholics than by controls. Twenty-hour-posttest urine volume and sodium excretion were reduced in alcoholics compared with controls.Conclusions: Despite their persistently decreased basal AVP plasma levels, long-term abstinent alcoholics have a well preserved AVP response to osmostimulation. This finding indicates a peripheral suppression of AVP levels that is most likely due to a regulatory set-point shift toward hypotonic hyperhydration, rather than to a reduced central capacity of AVP secretion."],["dc.identifier.gro","3150442"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7206"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.issn","0145-6008"],["dc.subject","Alcoholism; Abstinence; Antidiuretic Hormone; AVP; Osmolality"],["dc.title","Preserved vasopressin response to osmostimulation despite decreased basal vasopressin levels in long-term abstinent alcoholics"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1531"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Neurochemical Research"],["dc.bibliographiccitation.lastpage","1534"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Lewczuk, P."],["dc.contributor.author","Wiltfang, J."],["dc.contributor.author","Lange, M."],["dc.contributor.author","Jahn, H."],["dc.contributor.author","Reiber, H."],["dc.contributor.author","Ehrenreich, H."],["dc.date.accessioned","2017-09-07T11:44:45Z"],["dc.date.available","2017-09-07T11:44:45Z"],["dc.date.issued","2003"],["dc.description.abstract","Prothrombin, known to be expressed in brain and to possess growth modulating properties, has been suggested to be involved in the pathogenesis of Alzheimer's disease (AD). We studied prothrombin concentration in lumbar CSF (L-CSF) in patients with AD (n = 25), neurologic disease controls (NDC; n = 33) covering a wide range of neurologic disorders, and subjects with Guillain-Barré syndrome (GBS; n = 4) as well as in samples of non-pathological ventricular CSF (V-CSF; n = 4). The results were evaluated with respect to CSF flow rate, as indicated by the albumin quotient (QAlb). The concentrations of prothrombin in L-CSF in NDC (mean: 0.46 mg/l, range: 0.21–0.96), and AD (mean: 0.6 mg/l, range: 0.19–1.2) were in the normal range reported previously. Expectedly, prothrombin concentration in L-CSF of GBS was increased (mean: 6.3 mg/l, range: 2.3–9.7) corresponding to the increased QAlb in this group (mean 54.6 × 10−3, range: 17–88.1). The concentrations of both prothrombin and albumin were 5.5-fold higher in L-CSF than in V-CSF (mean QAlb : 1.1 × 10−3, mean concentration of prothrombin: 0.088 mg/l). In conclusion, CSF prothrombin in all conditions evaluated here is exclusively derived from blood."],["dc.identifier.doi","10.1023/a:1021147914843"],["dc.identifier.gro","3151739"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8560"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.notes.submitter","chake"],["dc.relation.issn","0364-3190"],["dc.title","Prothrombin Concentration in the Cerebrospinal Fluid Is Not Altered in Alzheimer's Disease"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","206"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Molecular Psychiatry"],["dc.bibliographiccitation.lastpage","220"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.contributor.author","Hinze-Selch, D."],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Aust, Carlotta"],["dc.contributor.author","Knolle-Veentjer, S."],["dc.contributor.author","Wilms, S."],["dc.contributor.author","Heinz, G."],["dc.contributor.author","Erdag, S."],["dc.contributor.author","Jahn, H."],["dc.contributor.author","Degner, Detlef"],["dc.contributor.author","Ritzen, M."],["dc.contributor.author","Mohr, Alexander"],["dc.contributor.author","Wagner, M."],["dc.contributor.author","Schneider, U."],["dc.contributor.author","Bohn, Matthias"],["dc.contributor.author","Huber, Martin"],["dc.contributor.author","Czernik, Adelheid"],["dc.contributor.author","Pollmacher, T."],["dc.contributor.author","Maier, Wolfgang"],["dc.contributor.author","Sirén, A-L."],["dc.contributor.author","Klosterkötter, J."],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Rüther, Eckart"],["dc.contributor.author","Aldenhoff, Josef B."],["dc.contributor.author","Krampe, Henning"],["dc.date.accessioned","2017-09-07T11:46:24Z"],["dc.date.available","2017-09-07T11:46:24Z"],["dc.date.issued","2007"],["dc.description.abstract","Schizophrenia is increasingly recognized as a neurodevelopmental disease with an additional degenerative component, comprising cognitive decline and loss of cortical gray matter. We hypothesized that a neuroprotective/neurotrophic add-on strategy, recombinant human erythropoietin (rhEPO) in addition to stable antipsychotic medication, may be able to improve cognitive function even in chronic schizophrenic patients. Therefore, we designed a double-blind, placebo-controlled, randomized, multicenter, proof-of-principle (phase II) study. This study had a total duration of 2 years and an individual duration of 12 weeks with an additional safety visit at 16 weeks. Chronic schizophrenic men (N=39) with defined cognitive deficit (greater than or equal to1 s.d. below normal in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)), stable medication and disease state, were treated for 3 months with a weekly short (15 min) intravenous infusion of 40 000 IU rhEPO (N=20) or placebo (N=19). Main outcome measure was schizophrenia-relevant cognitive function at week 12. The neuropsychological test set (RBANS subtests delayed memory, language–semantic fluency, attention and Wisconsin Card Sorting Test (WCST-64) – perseverative errors) was applied over 2 days at baseline, 2 weeks, 4 weeks and 12 weeks of study participation. Both placebo and rhEPO patients improved in all evaluated categories. Patients receiving rhEPO showed a significant improvement over placebo patients in schizophrenia-related cognitive performance (RBANS subtests, WCST-64), but no effects on psychopathology or social functioning. Also, a significant decline in serum levels of S100B, a glial damage marker, occurred upon rhEPO. The fact that rhEPO is the first compound to exert a selective and lasting beneficial effect on cognition should encourage new treatment strategies for schizophrenia."],["dc.identifier.doi","10.1038/sj.mp.4001907"],["dc.identifier.gro","3150509"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7281"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.issn","1359-4184"],["dc.subject","S100B; plasticity; neuropsychology; psychopathology; high-dose EPO"],["dc.title","Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]